8-K: Eliem Therapeutics Rebrands as Climb Bio, Inc., Ticker Symbol Changes to CLYM

Eliem Therapeutics, Inc. has officially changed its name to Climb Bio, Inc., effective October 2, 2024, and will begin trading under the new ticker symbol CLYM on Nasdaq starting October 3, 2024.

Summary

• Eliem Therapeutics, Inc. has changed its name to Climb Bio, Inc., effective as of 4:00 p.m. Eastern Time on October 2, 2024.
• The company's ticker symbol on the Nasdaq Global Market will change to CLYM, with trading under the new name and symbol expected to commence on October 3, 2024.
• The CUSIP number for the company's common stock will remain unchanged.
• The name change was approved by the Board of Directors and does not affect the rights of the company's stockholders.
• The company's Amended and Restated Bylaws were also amended to reflect the name change, effective October 2, 2024.

Sentiment

Score: 7

Explanation: The document reflects a neutral corporate action with no significant positive or negative implications. The change is expected and well-communicated.

Positives

• The name change is a straightforward corporate action that does not negatively impact shareholders.
• The company has clearly communicated the name and ticker symbol change to the market.
• The CUSIP number remaining the same simplifies the transition for investors.

Future Outlook

The company expects to begin trading under the new name and ticker symbol on October 3, 2024.

Management Comments

• The Board of Directors of the Company approved the Name Change pursuant to Section 242 of the General Corporation Law of the State of Delaware.

Industry Context

Name changes are not uncommon in the biotech industry, often reflecting a shift in strategic focus or a desire to rebrand the company's image. This change appears to be a standard corporate action.

Comparison to Industry Standards

• Many biotech companies undergo rebranding exercises to better reflect their current focus or future aspirations.
• The process of changing a company name and ticker symbol is a standard corporate procedure, and this announcement aligns with typical industry practices.
• The company has followed the standard legal and regulatory requirements for a name change.

Corporate Governance

Stakeholder Impact

• Shareholders will need to be aware of the ticker symbol change to CLYM.
• The name change does not affect the rights of the company's stockholders.

Next Steps

• The company will begin trading under the new name and ticker symbol CLYM on October 3, 2024.

Key Dates

Keywords

Climb Bio, Eliem Therapeutics, Name Change, Ticker Symbol, CLYM, Nasdaq, Corporate Rebranding